The choice of stem length in total hip revision with impaction bone grafting of femur is essentially based upon the grade of cavitation of femur and surgeon's preference. The standard length stem has been often critiqued for the apprehension of peri-prosthetic fracture. Our study highlights the importance of proximal bone stock rather than distal cavitation in determining the length of femoral stem. 168 total hip revisions of 162 patients with impaction bone grafting and cemented standard C-stem (done with standardized technique) between 1995 and 2008 at a tertiary referral centre were included. Revisions for infection and segmental bone defects were excluded. Serial radiographs were retrospectively analysed by two people independently, using Endoklinik classification, Gruen zones and more and outcomes were analysed. Mean follow-up of the 168 revision hips was 10.5 years (range 5 – 19.1 years). 14 patients (8.3%) were re-revised, reasons being, persistent deep infection (1.8%), repeated dislocations (1.2%), cup loosening (4.8%) and stem loosening (1.2%). Only 1 patient (0.6%) was re-revised due to stem loosening alone. No peri-prosthetic fractures or stem breakage were identified. Use of standard stem length in hip revisions with impaction bone grafting doesn't increase the risk of peri-prosthetic fractures even during long term follow up period. This questions the principle of bypassing the distal cavitation of femur by 2 cortical diameters with the use of long stem. In our experience, a good proximal femur support aids in the performance of standard length cemented stems in revision for aseptic loosening irrespective of grade of distal cavitation for cavitory defects of femur treated with impaction bone grafting.
Financial impact and patient satisfaction with four different anticoagulants for hip and knee arthroplasty in patients with a previous history of VTE- A prospective randomised trial New generation oral anticoagulants (dabigatran/rivaroxaban) have recently become available for the prevention of venous thromboembolism (VTE) following hip and knee arthroplasty. Traditional therapies (warfarin/low molecular weight heparins) are less costly, but have several limitations. The aim of this study was to evaluate the financial impact of substituting enoxaparin and warfarin with newer therapies dabigatran and rivaroxaban. A secondary objective was to investigate patient satisfaction with these treatments. A randomised prospective study was conducted over a 12 month period. Patients with a history of VTE undergoing hip or knee replacement were randomised to receive one of four anticoagulants for five weeks post surgery. Information was gathered during the hospital stay and then post discharge, by telephone, for five weeks(35 days)to determine costs. The costs included cost of drug, nursing time, blood monitoring and transport costs. The patients were also asked to complete the Duke Anticoagulation Satisfaction Scale (DASS). The DASS is a 26 item questionnaire which has 7 responses for each question.Introduction
Methods
